HIV-1 Tat B-cell epitope vaccination was ineffectual in preventing viral rebound after ART cessation

References

• Brumme ZL, Walker BD. Tracking the culprit: HIV-1 evolution and immune selection revealed by single-genome amplification. J Exp Med 2009; 206:1215 - 8; http://dx.doi.org/10.1084/jem.20091094; PMID: 19487418
   PubMed Web of Science ®Google Scholar
• McMichael AJ, Borrow P, Tomaras GD, Goonetilleke N, Haynes BF. The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol 2010; 10:11 - 23; http://dx.doi.org/10.1038/nri2674; PMID: 20010788
   PubMed Web of Science ®Google Scholar
• Stacey AR, Norris PJ, Qin L, Haygreen EA, Taylor E, Heitman J, et al. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol 2009; 83:3719 - 33; http://dx.doi.org/10.1128/JVI.01844-08; PMID: 19176632
   PubMed Web of Science ®Google Scholar
• Chang HC, Samaniego F, Nair BC, Buonaguro L, Ensoli B. HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region. AIDS 1997; 11:1421 - 31; http://dx.doi.org/10.1097/00002030-199712000-00006; PMID: 9342064
   PubMed Web of Science ®Google Scholar
• Li CJ, Ueda Y, Shi B, Borodyansky L, Huang L, Li YZ, et al. Tat protein induces self-perpetuating permissivity for productive HIV-1 infection. Proc Natl Acad Sci USA 1997; 94:8116 - 20; http://dx.doi.org/10.1073/pnas.94.15.8116; PMID: 9223324
   PubMed Web of Science ®Google Scholar
• Sahaf B, Atkuri K, Heydari K, Malipatlolla M, Rappaport J, Regulier E, et al. Culturing of human peripheral blood cells reveals unsuspected lymphocyte responses relevant to HIV disease. Proc Natl Acad Sci USA 2008; 105:5111 - 6; http://dx.doi.org/10.1073/pnas.0712363105; PMID: 18364393
   PubMed Web of Science ®Google Scholar
• Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?. Annu Rev Immunol 2001; 19:163 - 96; http://dx.doi.org/10.1146/annurev.immunol.19.1.163; PMID: 11244034
   PubMed Web of Science ®Google Scholar
• Charles P, Elliott MJ, Davis D, Potter A, Kalden JR, Antoni C, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 1999; 163:1521 - 8; PMID: 10415055
   PubMed Web of Science ®Google Scholar
• Lazdins JK, Grell M, Walker MR, Woods-Cook K, Scheurich P, Pfizenmaier K. Membrane tumor necrosis factor (TNF) induced cooperative signaling of TNFR60 and TNFR80 favors induction of cell death rather than virus production in HIV-infected T cells. J Exp Med 1997; 185:81 - 90; http://dx.doi.org/10.1084/jem.185.1.81; PMID: 8996244
   PubMed Web of Science ®Google Scholar
• Horiuchi T, Mitoma H, Harashima S, Tsukamoto H, Shimoda T. Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology (Oxford) 2010; 49:1215 - 28; http://dx.doi.org/10.1093/rheumatology/keq031; PMID: 20194223
   PubMed Web of Science ®Google Scholar
• Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004; 38:1261 - 5; http://dx.doi.org/10.1086/383317; PMID: 15127338
   PubMed Web of Science ®Google Scholar
• Goldstein G. HIV-1 Tat protein as a potential AIDS vaccine. Nat Med 1996; 2:960 - 4; http://dx.doi.org/10.1038/nm0996-960; PMID: 8782444
   PubMed Web of Science ®Google Scholar
• Longo O, Tripiciano A, Fiorelli V, Bellino S, Scoglio A, Collacchi B, et al. Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up. Vaccine 2009; 27:3306 - 12; http://dx.doi.org/10.1016/j.vaccine.2009.01.090; PMID: 19208456
   PubMed Web of Science ®Google Scholar
• Ensoli B, Fiorelli V, Ensoli F, Lazzarin A, Visintini R, Narciso P, et al. The preventive phase I trial with the HIV-1 Tat-based vaccine. Vaccine 2009; 28:371 - 8; http://dx.doi.org/10.1016/j.vaccine.2009.10.038; PMID: 19879233
   PubMed Web of Science ®Google Scholar
• Ensoli B, Bellino S, Tripiciano A, Longo O, Francavilla V, Marcotullio S, et al. Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART. PLoS ONE 2010; 5:e13540; http://dx.doi.org/10.1371/journal.pone.0013540; PMID: 21085635
   PubMed Web of Science ®Google Scholar
• Goldstein G, Tribbick G, Manson K. Two B cell epitopes of HIV-1 Tat protein have limited antigenic polymorphism in geographically diverse HIV-1 strains. Vaccine 2001; 19:1738 - 46; http://dx.doi.org/10.1016/S0264-410X(00)00393-5; PMID: 11166899
   PubMed Web of Science ®Google Scholar
• Goldstein G, Chicca JJ 2nd. A universal anti-HIV-1 Tat epitope vaccine that is fully synthetic and self-adjuvanting. Vaccine 2010; 28:1008 - 14; http://dx.doi.org/10.1016/j.vaccine.2009.10.129; PMID: 19931501
   PubMed Web of Science ®Google Scholar
• Goldstein G, Chicca J. Exploratory clinical studies of a synthetic HIV-1 Tat epitope vaccine in asymptomatic treatment-naïve and antiretroviral-controlled HIV-1 infected subjects plus healthy uninfected subjects. Hum Vaccin Immunother 2012; 8:8; PMID: 22336878
   PubMed Web of Science ®Google Scholar
• García F, Plana M, Vidal C, Cruceta A, O’Brien WA, Pantaleo G, et al. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. AIDS 1999; 13:F79 - 86; http://dx.doi.org/10.1097/00002030-199907300-00002; PMID: 10449278
   PubMed Web of Science ®Google Scholar
• Harrigan PR, Whaley M, Montaner JS. Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy. AIDS 1999; 13:F59 - 62; http://dx.doi.org/10.1097/00002030-199905280-00001; PMID: 10371167
   PubMed Web of Science ®Google Scholar
• Ortiz GM, Nixon DF, Trkola A, Binley J, Jin X, Bonhoeffer S, et al. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. J Clin Invest 1999; 104:R13 - 8; http://dx.doi.org/10.1172/JCI7371; PMID: 10491418
   PubMedGoogle Scholar
• Neumann AU, Tubiana R, Calvez V, Robert C, Li TS, Agut H, et al, Comet Study Group. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. AIDS 1999; 13:677 - 83; http://dx.doi.org/10.1097/00002030-199904160-00008; PMID: 10397562
   PubMed Web of Science ®Google Scholar
• Davey RT Jr., Bhat N, Yoder C, Chun TW, Metcalf JA, Dewar R, et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci USA 1999; 96:15109 - 14; http://dx.doi.org/10.1073/pnas.96.26.15109; PMID: 10611346
   PubMed Web of Science ®Google Scholar
• García F, Plana M, Ortiz GM, Bonhoeffer S, Soriano A, Vidal C, et al. The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection. AIDS 2001; 15:F29 - 40; http://dx.doi.org/10.1097/00002030-200106150-00002; PMID: 11416735
   PubMed Web of Science ®Google Scholar
• Ruiz L, Carcelain G, Martínez-Picado J, Frost S, Marfil S, Paredes R, et al. HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection. AIDS 2001; 15:F19 - 27; http://dx.doi.org/10.1097/00002030-200106150-00001; PMID: 11416734
   PubMed Web of Science ®Google Scholar
• Fischer M, Hafner R, Schneider C, Trkola A, Joos B, Joller H, et al, Swiss HIV Cohort Study. HIV RNA in plasma rebounds within days during structured treatment interruptions. AIDS 2003; 17:195 - 9; http://dx.doi.org/10.1097/00002030-200301240-00009; PMID: 12545079
   PubMed Web of Science ®Google Scholar
• Palmer S, Maldarelli F, Wiegand A, Bernstein B, Hanna GJ, Brun SC, et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci USA 2008; 105:3879 - 84; http://dx.doi.org/10.1073/pnas.0800050105; PMID: 18332425
   PubMed Web of Science ®Google Scholar
• Steingrover R, Pogány K, Fernandez Garcia E, Jurriaans S, Brinkman K, Schuitemaker H, et al. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy. AIDS 2008; 22:1583 - 8; http://dx.doi.org/10.1097/QAD.0b013e328305bd77; PMID: 18670217
   PubMed Web of Science ®Google Scholar
• Joos B, Fischer M, Kuster H, Pillai SK, Wong JK, Böni J, et al, Swiss HIV Cohort Study. HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc Natl Acad Sci USA 2008; 105:16725 - 30; http://dx.doi.org/10.1073/pnas.0804192105; PMID: 18936487
   PubMed Web of Science ®Google Scholar